Get the Most Out of Your
Medicare Drug Plan in 2025
December 7 is the deadline to make Medicare Part D changes so they will be in effect for the entirety of 2025. Beneficiaries have two new benefits to take advantage of: An annual out-of-pocket maximum cap of $2,000, and the ability to enroll in the new Medicare Prescription Payment Plan which will allow beneficiaries to spread out their costs through interest-free monthly installments. The cap is automatic, but in order to have the payment plan begin in January, beneficiaries must do so during Open Enrollment.
Medicare Changes, Value Assessment Headline Hill Event
Last month, the Alliance teamed up with The Hill for a live-streamed panel discussion, “Bang for Your Buck: Get the Most from Your 2025 Medicare Drug Benefits.” The program highlighted major upcoming changes to Medicare Part D plans and introduced a new metric using real-world evidence to measure value.
Respiratory viruses like the flu can cause serious and sometimes life-threatening illness, particularly for those with weakened immune systems, older adults, and young children.
Experts Discuss the Latest in Alzheimer's at 17th Annual ACT-AD Meeting
“When you cross boundaries, there's a lot we can learn”
This month, more than 50 patient advocates, public and private researchers, and leaders from the National Institutes of Health (NIH) and the Food & Drug Administration (FDA) gathered in Washington, DC for our FDA/ACT-AD Allies meeting, to discuss some of the latest Alzheimer's and neurodegenerative disease research and clinical development.
New White Paper Urges CMS to Increase Access to Anti-Obesity Treatments
Despite having the authority to cover anti-obesity meds like Ozempic and Mounjaro under Medicare Part D, the Centers for Medicare & Medicaid Services (CMS) chooses to restrict coverage to life-changing treatments.
In a new white paperreleased by the Alliance in partnership with Akin Gump Strauss Hauer & Feld LLP, we urge CMS to make changes now to support beneficiaries who are impacted by obesity and related chronic conditions.
New Poll Reveals Bipartisan Support for Patient Access and Equity
Last month, the Alliance for Aging Research, Partnership to Fight Chronic Disease (PFCD) and Us Against Alzheimer's released new polling data highlighting that a bipartisan majority of voters believe Medicare beneficiaries should have access to FDA-approved early Alzheimer’s medications the same way they do for all other diseases.
Learn more about what our latest poll reveals about voter opinions toward access and equity in a new film produced by PFCD.
